Revolution Medicines’ (RVMD) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Revolution Medicines (NASDAQ:RVMD – Free Report) in a research report released on Tuesday morning,Benzinga reports. They currently have a $350.00 price target on the stock.

A number of other research analysts have also commented on RVMD. Stifel Nicolaus upped their price objective on Revolution Medicines from $215.00 to $230.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. William Blair initiated coverage on Revolution Medicines in a report on Friday, October 16th. They set an “outperform” rating for the company. Oppenheimer boosted their target price on shares of Revolution Medicines from $230.00 to $260.00 and gave the company an “outperform” rating in a research report on Thursday, August 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a research report on Thursday, October 15th. Finally, Brookline Capital Markets started coverage on shares of Revolution Medicines in a research note on Monday, September 28th. They issued a “buy” rating and a $318.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Revolution Medicines currently has a consensus rating of “Moderate Buy” and a consensus price target of $262.75.

Get Our Latest Stock Analysis on RVMD

Revolution Medicines Trading Down 0.2%

Shares of NASDAQ RVMD opened at $159.43 on Tuesday. The company has a current ratio of 8.36, a quick ratio of 8.34 and a debt-to-equity ratio of 0.44. Revolution Medicines has a 1-year low of $69.50 and a 1-year high of $224.31. The business’s 50 day moving average is $190.87 and its 200-day moving average is $160.71.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($1.90) earnings per share for the quarter, topping the consensus estimate of ($2.35) by $0.45. The firm had revenue of $197.56 million for the quarter, compared to analyst estimates of $25.58 million. During the same period in the previous year, the business posted ($1.61) earnings per share. Analysts expect that Revolution Medicines will post -7.41 EPS for the current fiscal year.

Insider Activity at Revolution Medicines

In other news, Director Elizabeth Anderson sold 10,143 shares of Revolution Medicines stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $193.04, for a total value of $1,958,004.72. Following the completion of the sale, the director directly owned 4,333 shares in the company, valued at approximately $836,442.32. The trade was a 70.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Stephen Kelsey sold 92,531 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $202.36, for a total value of $18,724,573.16. Following the completion of the sale, the insider owned 291,876 shares of the company’s stock, valued at approximately $59,064,027.36. This trade represents a 24.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 273,901 shares of company stock valued at $53,970,418. 7.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Revolution Medicines

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Burkett Financial Services LLC bought a new stake in shares of Revolution Medicines during the 3rd quarter worth $27,000. Contravisory Investment Management Inc. acquired a new stake in Revolution Medicines in the second quarter valued at about $32,000. ABS Investment Management LLC acquired a new stake in Revolution Medicines in the second quarter valued at about $337,104,000. Johnson Financial Group Inc. acquired a new stake in Revolution Medicines in the second quarter valued at about $37,000. Finally, Mather Group LLC. bought a new position in Revolution Medicines in the third quarter valued at about $41,000. 94.34% of the stock is owned by institutional investors and hedge funds.

About Revolution Medicines

(Get Free Report)

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.

Recommended Stories

Analyst Recommendations for Revolution Medicines (NASDAQ:RVMD)

Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.